Research Topics
| J Craig NelsonSummaryAffiliation: University of California Country: USA Publications
| Collaborators
|
Detail Information
Publications
Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized studyJ Craig Nelson
Department of Psychiatry, University of California-San Francisco, 401 Parnassus Avenue, Box 0984-5, San Francisco, CA 94143, USA
Biol Psychiatry 55:296-300. 2004..CONCLUSIONS: This study supports the hypothesis that the combination of a noradrenergic and serotonergic agent is more likely to result in remission than either selective agent alone during a 6-week treatment period...
Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapyJames Craig Nelson
Department of Psychiatry, University of California San Francisco, 401 Parnassus Ave, San Francisco, CA 94143, USA
Int Clin Psychopharmacol 27:125-33. 2012..12%, respectively, P<0.0001). The numbers needed to treat with aripiprazole+ADT were six for response and eight for remission. Aripiprazole augmentation had a rapid and clinically meaningful effect in ADT minimal responders...- Predictors of remission with placebo using an integrated study database from patients with major depressive disorderJ C Nelson
Department of Psychiatry, University of California, San Francisco, CA 94143, USA
Curr Med Res Opin 28:325-34. 2012..To identify predictors of remission with placebo treatment in double-blind randomized controlled trials (RCTs) in major depressive disorder (MDD)... - Efficacy of second generation antidepressants in late-life depression: a meta-analysis of the evidenceJ Craig Nelson
Department of Psychiatry, University of California San Francisco, CA, USA
Am J Geriatr Psychiatry 16:558-67. 2008..This systematic review and meta-analysis was undertaken to assess the evidence for efficacy of second-generation antidepressants in late-life major depression... - Effects of aripiprazole adjunctive to standard antidepressant treatment on the core symptoms of depression: a post-hoc, pooled analysis of two large, placebo-controlled studiesJ Craig Nelson
University of California, San Francisco, California, USA
J Affect Disord 120:133-40. 2010..The objective of this study was to examine the effects of aripiprazole on core symptoms of depression... - Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trialsJ Craig Nelson
Department of Psychiatry, University of California San Francisco, 401 Parnassus Ave, Box 0984 F, San Francisco, CA 94143, USA
Am J Psychiatry 166:980-91. 2009..The authors sought to determine by meta-analysis the efficacy and tolerability of adjunctive atypical antipsychotic agents in major depressive disorder... - Suicidal thinking and behavior during treatment with sertraline in late-life depressionJ Craig Nelson
Department of Psychiatry, University of California San Francisco, San Franciso, CA, USA
Am J Geriatr Psychiatry 15:573-80. 2007..To determine effects of sertraline on suicidal thinking and behavior in patients with late-life major depression... - Are there predictors of outcome in depressed elderly nursing home residents during treatment with mirtazapine orally disintegrating tablets?J Craig Nelson
University California San Francisco, San Francisco, CA, USA
Int J Geriatr Psychiatry 22:999-1003. 2007..Treatment studies of depression in residential care are limited. Reports of predictors of response are rare. In the largest nursing home prospective antidepressant trial reported, we examined predictors of response... 
The safety and tolerability of duloxetine compared with paroxetine and placebo: a pooled analysis of 4 clinical trialsJ Craig Nelson
Department of Psychiatry, University of California at San Francisco, San Francisco, CA, USA
Prim Care Companion J Clin Psychiatry 8:212-9. 2006..8%; paroxetine, 13.8%; placebo, 3.1%), but the active-treatment groups did not differ. Conclusions: Duloxetine is safe and well tolerated in patients with MDD, with safety and tolerability comparable to that of paroxetine...- Residual symptoms in depressed patients after treatment with fluoxetine or reboxetineJ Craig Nelson
Department of Psychiatry, University of California San Francisco, 401 Parnassus Avenue, PO Box 0984 F, San Francisco, CA 94143, USA
J Clin Psychiatry 66:1409-14. 2005..We examined the frequency and severity of residual depressive symptoms in 2 studies comparing the selective serotonin reuptake inhibitor (SSRI) fluoxetine with the norepinephrine reuptake inhibitor (NRI) reboxetine... - Anxiety does not predict response to duloxetine in major depression: results of a pooled analysis of individual patient data from 11 placebo-controlled trialsJ Craig Nelson
Department of Psychiatry, University of California, San Francisco, California, USA
Depress Anxiety 27:12-8. 2010..The objective of this study is to determine whether specific antidepressant effects, estimated by drug-placebo differences, are reduced in anxious depression during treatment of MDD with duloxetine... - A systematic review and meta-analysis of placebo-controlled antidepressant studies in people with depression and dementiaJ Craig Nelson
Department of Psychiatry, University of California San Francisco, San Francisco, California, USA
J Am Geriatr Soc 59:577-85. 2011..To determine the efficacy of antidepressants in people with depression and dementia... - Safety and Tolerability of Adjunctive Aripiprazole in Major Depressive Disorder: A Pooled Post Hoc Analysis (studies CN138-139 and CN138-163)J Craig Nelson
Department of Psychiatry, University of California San Francisco, San Francisco, CA, USA
Prim Care Companion J Clin Psychiatry 11:344-52. 2009..To evaluate the safety and tolerability of aripiprazole adjunctive to standard antidepressant therapy (ADT) for patients with major depressive disorder (DSM-IV-TR criteria)... - Are there differences in the symptoms that respond to a selective serotonin or norepinephrine reuptake inhibitor?J Craig Nelson
Department of Psychiatry, University of California San Francisco, San Francisco, California 94143, USA
Biol Psychiatry 57:1535-42. 2005.... - Symptoms of late-life depression: frequency and change during treatmentJ Craig Nelson
Dept of Psychiatry, University of California at San Francisco, 401 Parnassus Ave, Box 0984 F, San Francisco, CA 94143, USA
Am J Geriatr Psychiatry 13:520-6. 2005.... - Anxiety does not predict response to antidepressant treatment in late life depression: results of a meta-analysisJ Craig Nelson
Department of Psychiatry, University of California San Francisco, CA, USA
Int J Geriatr Psychiatry 24:539-44. 2009..Our aim was to determine if anxiety predicts antidepressant response in previously identified placebo-controlled trials of second generation antidepressants for late-life depression... - Mirtazapine orally disintegrating tablets in depressed nursing home residents 85 years of age and olderJ Craig Nelson
Department of Psychiatry, University of California, San Francisco, USA
Int J Geriatr Psychiatry 21:898-901. 2006..The naturalistic conditions of the study allowed us to include patients with cognitive impairment, concomitant medications and comorbid illness... - Assessment of outcome in depressionJ Craig Nelson
Department of Psychiatry, University of California, San Francisco, CA, USA
J Psychopharmacol 20:47-53. 2006..And we review studies that have identified 'core' symptoms of depression and compare these findings to the magnitude of individual symptom change we found in five studies of selective serotonergic or nonadrenergic antidepressants... - Serum BDNF levels before treatment predict SSRI response in depressionOwen M Wolkowitz
Department of Psychiatry, University of California, San Francisco School of Medicine, San Francisco, CA 94143, United States
Prog Neuropsychopharmacol Biol Psychiatry 35:1623-30. 2011..It is also unknown whether pre-treatment serum BDNF levels predict antidepressant response... - A meta-analysis of clinical trials comparing reboxetine, a norepinephrine reuptake inhibitor, with selective serotonin reuptake inhibitors for the treatment of major depressive disorderGeorge I Papakostas
Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, 15 Parkman Street, WAC 812 Boston, MA 02114, USA
Eur Neuropsychopharmacol 18:122-7. 2008..These results suggest that the NRI reboxetine and the SSRIs differ with respect to their side-effect profile and overall tolerability but not their efficacy in treating MDD... - Duloxetine for the treatment of major depressive disorder in older patientsJ Craig Nelson
Department of Psychiatry, University of California at San Francisco, San Francisco, CA, USA
Am J Geriatr Psychiatry 13:227-35. 2005..CONCLUSIONS: In these two investigations, duloxetine 60 mg/day was an efficacious treatment for MDD and also alleviated pain symptoms in depression patients age 55 and older... - Augmentation and combination strategies in resistant depressionJ Craig Nelson
Department of Psychiatry, University of California School of Medicine, San Francisco, CA, USA
J Clin Psychiatry 70:e20. 2009..Clinical trials have assessed the efficacy of many agents commonly used for augmentation or combination therapy, but well-designed, large trials with a clear definition of treatment resistance are needed... - Managing treatment-resistant major depressionJ Craig Nelson
Department of Psychiatry, University of California, San Francisco 94143-0984, USA
J Clin Psychiatry 64:5-12. 2003..More research is needed that controls for continued time on the initial agent, that compares different strategies, and that determines which patients are the best candidates for which treatment... - Leukocyte telomere length in major depression: correlations with chronicity, inflammation and oxidative stress--preliminary findingsOwen M Wolkowitz
Department of Psychiatry, University of California San Francisco School of Medicine, San Francisco, California, United States of America
PLoS ONE 6:e17837. 2011..We sought to determine if leukocyte telomeres are shortened in Major Depressive Disorder (MDD), whether this is a function of lifetime depression exposure and whether this is related to putative mediators, oxidation and inflammation... - Are antidepressants effective? What's a clinician to think?J Craig Nelson
University of California, San Francisco, USA
J Clin Psychiatry 69:1014-5. 2008 - Augmentation strategies in the treatment of major depressive disorder. Recent findings and current status of augmentation strategiesJ Craig Nelson
Department of Psychiatry, University of California, San Francisco, USA
CNS Spectr 12:6-9. 2007 - Increased risk of cerebrovascular adverse events and death in elderly demented patients treated with atypical antipsychotics: what's a clinician to do?J Craig Nelson
University of California, San Francisco, USA
J Clin Psychiatry 66:1071. 2005 - Psychotic depression and mortalityMeena Vythilingam
Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA
Am J Psychiatry 160:574-6. 2003..The authors hypothesized that patients with psychotic depression would have higher mortality rates than patients with nonpsychotic depression... - Augmentation treatment in major depressive disorder: focus on aripiprazoleJ Craig Nelson
University of California San Francisco, San Francisco, California, USA
Neuropsychiatr Dis Treat 4:937-48. 2008..The availability of this new treatment option should allow more patients with MDD to achieve remission and, ultimately, long-term, successful outcomes... - Genotype-controlled analysis of plasma dopamine beta-hydroxylase activity in psychotic unipolar major depressionJoseph F Cubells
Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06516, USA
Biol Psychiatry 51:358-64. 2002..Plasma DbetaH is under genetic control by the structural locus encoding DbetaH protein, DBH. This study tested the hypothesis that diagnosis-specific allelic variation at DBH accounts for lower plasma DbetaH in UDPF... - Assessment and treatment of depression in disability claimants: a cost-benefit simulation studyAndrew C Leon
Weill Medical College of Cornell University, Department of Psychiatry, New York, New York 10021, USA
J Nerv Ment Dis 190:3-9. 2002..The economic and public health benefits both point toward the value of such an intervention for disability claimants...